Tingting Chen

Dr. Tingting Chen

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2023 in Frontiers in Genetics
Verified
Journal Article
Open access
YYYimin Yao
Yimin Yao
HCHaixin Chen
Haixin Chen
MLMinjun Lou
Minjun Lou
TCTingting Chen
Tingting Chen
Background: Kidney renal clear cell carcinoma (KIRC) is not sensitive to radiotherapy and chemotherapy, and only some KIRC patients can benefit from immunotherapy and targeted therapy. Cuproptosis is a new mechanism of cell death, which is closely related to tumor progression, prognosis and immunity. The identification of prognostic markers related to cuproptosis in KIRC may provide targets for treatment and improve the prognosis of KIRC patients.Methods: Ten cuproptosis-related genes were analyzed for differential expression in KIRC-TCGA and a prognostic model was constructed. Nomogram diagnostic model was used to screen independent prognostic molecules. The screened molecules were verified in multiple datasets (GSE36895 and GSE53757), and in KIRC tumor tissues by RT-PCR and immunohistochemistry (IHC). Clinical correlation of cuproptosis-related independent prognostic molecules was analyzed. According to the molecular expression, the two groups were divided into high and low expression groups, and the differences of immune checkpoint and tumor infiltrating lymphocytes (TILs) between the two groups were compared by EPIC algorithm. The potential Immune checkpoint blocking (ICB) response of high and low expression groups was predicted by the “TIDE” algorithm.Results: FDX1 and DLAT were protective factors, while CDKN2A was a risk factor. FDX1 was an independent prognostic molecule by Nomogram, and low expressed in tumor tissues compared with adjacent tissues (p < 0.05). FDX1 was positively correlated with CD274, HAVCR2, PDCD1LG2, and negatively correlated with CTLA4, LAG3, and PDCD1. The TIDE score of low-FDX1 group was higher than that of high-FDX1 group. The abundance of CD4+ T cells, CD8+ T cells and Endothelial cells in FDX1-low group was lower than that in FDX1-high group (p < 0.05).Conclusion: FDX1, as a key cuproptosis-related gene, was also an independent prognostic molecule of KIRC. FDX1 might become an interesting biomarker and potential therapeutic target for KIRC.

23 September 2021 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
PCPing Chen
Ping Chen
WLWei Lu
Wei Lu
TCTingting Chen
Tingting Chen
Objective: The purpose of this study was to analyze the levels of tumor‐associated autoantibodies (TAAbs) in lung diseases and determine their diagnostic efficiency in early‐stage non‐small cell lung cancer (NSCLC).Methods: We retrospectively analyzed the levels of 7‐TAAbs in 177 newly diagnosed early‐stage NSCLC patients, 202 patients with lung benign diseases and 137 healthy cases. The levels of a panel of 7‐TAAbs, including p53, GAGE7, PGP9.5, CAGE, MAGE A1, SOX2, GBU4‐5, were measured by ELISA.Results: The serum levels of p53, GAGE7, PGP9.5, CAGE, MAGE A1, SOX2, and GBU4‐5 were not statistically different among NSCLC, benign and healthy groups (p > 0.05). The area under the curve (AUC) of 7‐TAAbs was all lower than 0.70. The sensitivity of combined detection was the highest (23.73%), while the specificity was the lowest (88.79%). The positive rates of PGP9.5, SOX2, and combined detection were significantly different among the three groups (p < 0.05). Among them, PGP9.5 and combined detection were significantly different between the NSCLC and benign groups (p < 0.05), PGP9.5, SOX2 and combined detection were significantly different between the NSCLC and healthy groups (p < 0.05).Conclusions: The diagnostic efficiency of 7‐TAAbs in early‐stage NSCLC was not high, so it cannot be used alone as a screening method for NSCLC.

5 February 2021 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
PDF file
WLWei Lu
Wei Lu
YLYao Lu
Yao Lu
CWChun‐Feng Wang
Chun‐Feng Wang
TCTingting Chen
Tingting Chen
Background: Myasthenia gravis (MG) is an autoimmune disease mediated by acetylcholine receptor antibodies. Exosomes were shown to be involved in the immune modulation and autoimmune diseases. However, the expression and function of exosomal long noncoding RNAs (lncRNAs) in MG are still unclear.Methods: We conducted high‐throughput sequencing to detect the lncRNA profiles of serum exosomes in 6 MG patients (2 grade I, 2 grade IIa, and 2 grade IIb) and 6 healthy controls (HC). Then, differentially expressed (DE) lncRNAs with the greatest difference between the MG and HC groups were selected for further quantitative real‐time polymerase chain reaction (qRT‐PCR) validation in additional 30 MG patients and 10 HC. The DE lncRNAs were used to construct the coding/noncoding network and perform enrichment analysis.Results: We identified 378 significantly upregulated and 348 significantly downregulated lncRNAs in MG patients compared with HC. The top 5 lncRNAs (NR_104677.1, ENST00000583253.1, NR_046098.1, NR_022008.1, and ENST00000581362.1) were validated and shown to be significantly increased in the serum exosome of MG, and the expression level of NR_046098.1 significantly increased with the MG grading. Enrichment analysis showed that DE genes mainly participated in the basic biological regulation of MG and immune‐related pathways, such as autoimmune thyroid disease pathway and T‐cell receptor signaling pathway. A specific lncRNA‐miRNA‐mRNA regulatory network associated with the 5 lncRNAs, 14 MG‐related miRNAs and 30 mRNAs was constructed.Conclusions: We conducted a comprehensive analysis of exosomal lncRNAs to reveal potential biomarkers for the MG diagnosis and severity assessment.

5 September 2025 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YSYuxin Shang
Yuxin Shang
YPYuqing Pan
Yuqing Pan
LXLingling Xie
Lingling Xie
YZYan Zhao
Yan Zhao
WMWei Mao
Wei Mao
TCTingting Chen
Tingting Chen
Atherosclerosis, the leading cause of cardiovascular morbidity and mortality worldwide, is now firmly established as a chronic immune-mediated disorder rather than a purely lipid-storage disease. Accumulating evidence has uncovered a previously underappreciated dimension of atherogenesis: the dynamic and bidirectional crosstalk between the nervous and immune systems. This neuroimmune axis, involving intricate communication between autonomic neural circuits and vascular immune cells, plays a central role in regulating arterial inflammation and plaque development. In particular, neuroimmune cardiovascular interfaces (NICIs)—specialized anatomical and functional hubs—have emerged as key sites for signal integration. Here, we review recent mechanistic insights into how sympathetic and parasympathetic pathways influence immune responses in atherosclerotic vessels and hematopoietic organs. We focus on the roles of neuromodulators such as pituitary adenylate cyclase-activating polypeptide (PACAP), calcitonin gene-related peptide (CGRP), neuropeptide Y (NPY), and galanin in shaping myeloid cell behavior, vascular tone, and endothelial activation. Additionally, we examine translational advances in neuromodulatory interventions—ranging from vagus nerve stimulation (VNS) to selective α7 nicotinic acetylcholine receptor (α7nAChR) agonists—that target these pathways to mitigate vascular inflammation in experimental models. These findings suggest that spatially resolved and temporally dynamic neuroimmune interactions constitute a critical layer of regulation in atherogenesis, offering a compelling framework for novel anti-inflammatory therapies beyond traditional lipid-lowering strategies.

22 July 2025 in Ecotoxicology and Environmental Safety
Verified
Journal Article
Open access
LXLingling Xie
Lingling Xie
YZYan Zhao
Yan Zhao
YPYuqing Pan
Yuqing Pan
YSYuxin Shang
Yuxin Shang
YKYoujin Kong
Youjin Kong
WMWei Mao
Wei Mao
This study employed a network toxicology strategy to elucidate the toxic mechanisms of polyethylene terephthalate microplastics (PET-MPs) on atherosclerosis (AS). AS is a chronic inflammatory vascular disease that may be aggravated by PET-MPs. By integrating network toxicology, molecular docking, and transcriptome analysis, tumor necrosis factor (TNF), chemokine receptor 4 (CXCR4), CX3C chemokine receptor 1 (CX3CR1), and protein tyrosine phosphatase receptor type C (PTPRC) were identified as core interaction genes between PET and AS. Through bio-enrichment analysis, we discovered that the toxicity of PET is primarily associated with the cascade reaction of vascular inflammation and abnormal macrophage activation. Molecular docking experiments confirmed a strong binding affinity between PET and these targets (<-5.0 kcal/mol). In vitro results showed that PET significantly increased the mRNA levels of TNF-α, CXCR4, CX3CR1, and PTPRC, triggering an inflammatory response and causing chemokine receptor dysfunction. In an AS mouse model, increased aortic plaque area and aortic valve collagen deposition were observed, along with elevated expression of core target genes' mRNA, even without direct exposure to PET-MPs, exhibiting effects consistent with those seen in vitro. Collectively, these studies suggest that PET can induce inflammatory responses and disrupt immune system balance by regulating the expression levels of TNF, CXCR4, CX3CR1, and PTPRC, thus promoting the progression of atherosclerotic diseases. This paper provides the first comprehensive investigation into the impact and mechanisms of microplastics on AS, demonstrating how PET contributes to its development and establishing a basis for identifying new therapeutic targets for cardiovascular diseases linked to microplastics.

14 May 2024 in Frontiers in Genetics
Verified
Journal Article
Open access
PDF file
XLXinyi Li
Xinyi Li
LXLingling Xie
Lingling Xie
JDJin Dai
Jin Dai
XZXinbin Zhou
Xinbin Zhou
TCTingting Chen
Tingting Chen
WMWei Mao
Wei Mao
Background: Patent foramen ovale (PFO) has a genetic predisposition and is closely associated with cryptogenic stroke (CS), migraine, decompression sickness, and hypoxemia. Identifying PFO-related mutant genes through whole-exome sequencing (WES) can help in the early recognition of cardiovascular genetic risk factors, guide timely clinical intervention, and reduce the occurrence of cardiovascular events.Methods: We analyzed mutant genes from ClinVar and OMIM databases. WES was performed on 25 PFO patients from Zhejiang Provincial Hospital of Chinese Medicine. Pathogenicity of variants was evaluated using American College of Medical Genetics and Genomics (ACMG) and Association for Molecular Pathology. (AMP) guidelines.Results: In ClinVar (4 Feb 2023), 113 coding gene mutations were found, including 83 associated with PFO. From OMIM (18 Apr 2023), 184 gene mutations were analyzed, with 110 mutant coding genes. WES identified pathogenic mutations in two of 25 PFO patients (8%). LDLR, SDHC, and NKX2-5 genes were linked to PFO and primarily involved in myocardial tissue function. NKX2-5 may play a crucial role in PFO development, interacting with NOTCH1, GATA4, MYH6, SCN5A signaling pathways regulating cardiomyocyte characteristics.Conclusion: We identified pathogenic mutations in LDLR, SDHC, and NKX2-5 genes, implying their role in PFO development. Functional enrichment analysis revealed NKX2-5’s interaction with signaling pathways regulating cardiomyocyte function. These findings enhance our understanding of PFO’s genetic basis, suggesting potential therapeutic targets for future research.